It has been a busy week for psychedelic medicines developer Cybin, marked by a breakthrough designation (BTD) from the FDA for its depression therapy, new clinical data, a
The Peterson Health Technology Institute (PHTI) has added hypertension and mental health to the list of digital health technologies (DHTs) that it will review for their cl
Doctors should think twice before prescribing drug therapies when faced with someone battling depression, as exercise may be more effective, according to a new study.
Alto Neuroscience has said its therapeutic approach to depression of matching patients to drugs based on brain biomarkers has shown promise in a phase 2a trial.
Cybin has unveiled phase 2 results with its psychedelic medicine for major depressive disorder, which it says support moving the drug into a phase 3 programme.
People with depression can sometimes have impaired memory, particularly for positive events, which can contribute to cognitive problems and impair their daily lives.
Today, pharma brand planning teams can benefit from technology platforms that aggregate data and automate analyses, helping unlock insights on the market landscape and clinical environment